Literature DB >> 21481528

Molecular portraits of intratumoral heterogeneity in human ovarian cancer.

Yoon Pyo Choi1, Hyo Sup Shim2, Ming-Qing Gao1, Suki Kang2, Nam Hoon Cho3.   

Abstract

One of the most common characteristic profiles of cancer is intratumoral heterogeneity (ITH). We aimed to clarify the molecular profiles and biological significance of ITH with relation to cancer stem cell (CSC). We analyzed five primary cultured clones generated from different spatial zones, front and rear zone, of a fresh-frozen ovarian tumor tissue, performing ATP-CRA, conventional RT-PCR, side population (SP) analysis, flow cytometry immunophenotyping, and cell proliferation assays. We also carried out array CGH and Ingenuity Pathways Analysis (IPA) between SP and non-SP (NSP) cells. Clones from tumor front zone showed phenotypically and genetically distinct subpopulations with relatively higher SP proportions, CD24(+) and CD117(+) expression, and chemotherapeutic resistance. We demonstrate that phenotype of SP cells in heterogeneous clones of human ovarian cancer was closely related to CD24(+), CD117(+), and combined CD117(+)/CD24(+) fractions. Chromosomal alterations in SP cells relative to NSP cells were closely related to the novel core networks of cancer stem cell-like cells (CSCs), such as cycle checkpoint regulation, notch, PTEN, wnt/β-catenin, PI3K/AKT, integrin, and cytokine and chemokine signaling. ITH could arise from clonal diversity closely related to CSC-like molecules, as evidenced by accumulated genetic, transcriptional and gene products alterations in SP.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481528     DOI: 10.1016/j.canlet.2011.03.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

Review 1.  Tumor heterogeneity and its implication for drug delivery.

Authors:  Tracy A Denison; You Han Bae
Journal:  J Control Release       Date:  2012-04-15       Impact factor: 9.776

2.  Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.

Authors:  Stine E Weis-Banke; Mads Lerdrup; Daniela Kleine-Kohlbrecher; Faizaan Mohammad; Simone Sidoli; Ole N Jensen; Toshihiko Yanase; Tomoko Nakamura; Akira Iwase; Anthe Stylianou; Nadeem R Abu-Rustum; Carol Aghajanian; Robert Soslow; Arnaud Da Cruz Paula; Richard P Koche; Britta Weigelt; Jesper Christensen; Kristian Helin; Paul A C Cloos
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

3.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

Review 4.  Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Authors:  Daniela Burgos-Ojeda; Bo R Rueda; Ronald J Buckanovich
Journal:  Cancer Lett       Date:  2012-02-11       Impact factor: 8.679

5.  Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

Authors:  Hilda Wong; Thomas Yau
Journal:  Oncologist       Date:  2012-02-14

Review 6.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

7.  Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.

Authors:  Rachel Eyre; Ian Harvey; Katherine Stemke-Hale; Thomas W J Lennard; Alison Tyson-Capper; Annette P Meeson
Journal:  Tumour Biol       Date:  2014-07-04

8.  Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel.

Authors:  Jennifer H Granger; Michael C Granger; Matthew A Firpo; Sean J Mulvihill; Marc D Porter
Journal:  Analyst       Date:  2013-01-21       Impact factor: 4.616

Review 9.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

10.  Honokiol as a Radiosensitizing Agent for Colorectal cancers.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Zhongtao Zhang; Youcheng Zhang; Shrikant Anant
Journal:  Curr Colorectal Cancer Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.